V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Phathom Pharmaceuticals Executive Compensation (FY25)

PHAT · Florham Park, NJ · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Steven Basta
Latest say-on-pay support
=
May 19, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Phathom Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 21, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Phathom Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
168 figures on this page: 166 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.

More on Phathom Pharmaceuticals

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Terrie Curran → Steven Basta

Frequently asked questions

Answers drawn from the data on this page.
Who is Phathom Pharmaceuticals' chief executive and what were they paid?
Total compensation for Steven Basta, President and Chief Executive Officer, came to $6,968,070 in fiscal 2025.
What was Phathom Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 94.6% of votes cast for or against in favor at the meeting held May 19, 2026.
Which companies are in Phathom Pharmaceuticals' peer group?
The disclosed peer group names Aclaris Therapeutics, Inc., Arcus Biosciences, Inc., Arcutis Biotherapeutics, Inc., Ardelyx, Inc. and Biohaven Ltd., among others. The 2025 Compensation Peer Group includes Arcus Biosciences, Inc., Arcutis Biotherapeutics, Inc., Ardelyx, Inc., Cogent Biosciences, Inc. and Collegium Pharmaceuticals, Inc., among others. The 2026 Compensation Peer Group names Biohaven Ltd., Esperion Therapeutics, Inc., KalVista Pharmaceuticals, Inc., Kura Oncology, Inc. and Nuvation Bio Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Terrie Curran
President and Chief Executive Officer
◇——◇◇—◇◇
Azmi Nabulsi
Chief Operating Officer
◇——◇◇—◇◇
Molly Henderson
Chief Financial and Business Officer
◇◇—◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Terrie Curran
President and Chief Executive Officer
◇—◇◇◇—◇◇
Azmi Nabulsi
Chief Operating Officer
◇—◇◇◇—◇◇
Molly Henderson
Chief Financial and Business Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Terrie Curran
Former President and Chief Executive Officer
◇——◇◇—◇◇
Azmi Nabulsi
Former Chief Operating Officer
◇—◇◇◇—◇◇
Molly Henderson
Chief Financial and Business Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Steven Basta
President and Chief Executive Officer
◇—◇◇◇—◇◇
Terrie Curran
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Sanjeev Narula
Chief Financial and Business Officer
◇—◇◇◇—◇◇
Azmi Nabulsi
Former Chief Operating Officer
Departed during or after this year
◇—◇◇——◇◇
Anne Marie Cook
Chief Legal Officer and Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Anne Marie CookPSU◇—◇————
Azmi NabulsiRSU———————
Sanjeev NarulaRSU◇——◇——◇
Steven BastaPSU◇—◇————
Terrie CurranPSU◇—◇————
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Steven BastaPSU◇◇——
PSU◇◇——
Option◇—◇4/2/2035
Sanjeev NarulaRSU◇◇——
Option◇—◇10/5/2035
Azmi NabulsiRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/18/2032
Option◇—◇1/18/2033
Option◇—◇1/17/2034
Option◇—◇2/26/2035
Anne Marie CookPSU◇◇——
Option◇—◇6/22/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Sanjeev Narula
Chief Financial and Business Officer · Terms as announced by the company
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Theodore R. Schroeder
◇◇◇———◇
Michael F. Cola
Board chair
◇◇◇———◇
Heidi Kunz
◇◇◇———◇
Asit Parikh
◇◇◇———◇
Frank Karbe
◇◇◇———◇
Mark Stenhouse
◇◇◇———◇
James Topper
◇◇◇———◇
David Socks
◇—————◇
Steven Basta served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Aclaris Therapeutics, Inc. ACRS
  • Arcus Biosciences, Inc. RCUS
  • Arcutis Biotherapeutics, Inc. ARQT
  • Ardelyx, Inc. ARDX
  • Biohaven Ltd. BHVN
  • Cogent Biosciences, Inc. COGT
  • Coherus Biosciences, Inc. CHRS
  • Collegium Pharmaceuticals, Inc. AMPH
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Deciphera Pharmaceuticals, Inc. DCPH
  • Esperion Therapeutics, Inc. ESPR
  • Evolus, Inc. EOLS
  • Humacyte, Inc. HUMA
  • Intercept Pharmaceuticals, Inc. ICPT
  • Ironwood Pharmaceuticals, Inc. IRWD
  • KalVista Pharmaceuticals, Inc. KALV
  • Kura Oncology, Inc. KURA
  • Mirum Pharmaceuticals, Inc. MIRM
  • Nuvation Bio Inc. NUVB
  • Protagonist Therapeutics, Inc. PTGX
  • REGENXBIO Inc. RGNX
  • Revance Therapeutics, Inc. RVNC
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Rocket Pharmaceuticals, Inc. RCKT
  • Seres Therapeutics, Inc. MCRB
  • Syndax Pharmaceuticals, Inc. SNDX
  • Tarsus Pharmaceuticals, Inc. TARS
  • Travere Therapeutics, Inc. TVTX
  • UroGen Pharma Ltd. URGN
  • Xeris Biopharma Holdings, Inc. XERS
2025 Compensation Peer Group
  • Arcus Biosciences, Inc. RCUS
  • Arcutis Biotherapeutics, Inc. ARQT
  • Ardelyx, Inc. ARDX
  • Cogent Biosciences, Inc. COGT
  • Collegium Pharmaceuticals, Inc. COLL
  • Evolus, Inc. EOLS
  • Humacyte, Inc. HUMA
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Mirum Pharmaceuticals, Inc. MIRM
  • Protagonist Therapeutics, Inc. PTGX
  • Revance Therapeutics, Inc. RVNC
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Rocket Pharmaceuticals, Inc. RCKT
  • Tarsus Pharmaceuticals, Inc. TARS
  • Travere Therapeutics, Inc. TVTX
  • UroGen Pharma Ltd. URGN
2026 Compensation Peer Group
  • Biohaven Ltd. BHVN
  • Esperion Therapeutics, Inc. ESPR
  • KalVista Pharmaceuticals, Inc. KALV
  • Kura Oncology, Inc. KURA
  • Nuvation Bio Inc. NUVB
  • REGENXBIO Inc. RGNX
  • Syndax Pharmaceuticals, Inc. SNDX
  • Xeris Biopharma Holdings, Inc. XERS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 19, 2026=◇◇◇
2024June 3, 2025=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Steven Basta (President and Chief Executive Officer), FY2025 total compensation $6,968,070 (base salary $525,000) [exec_comp, SEC accession 0001193125-26-144570, filed 2026-04-07]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Phathom Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Phathom Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Phathom Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Phathom Pharmaceuticals' disclosed peer group is defensible, who names Phathom Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
168 figures on this page: 166 cited to the filing that reported them, 2 calculated from figures it prints.
166 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001193125-26-234379
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-144570
    LOSED IN THIS PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SEC. &
  3. 0001193125-25-230984
    Exhibit
  4. 0001193125-25-137800
  5. 0000950170-25-057326
    Summary Compensation Table
  6. 0000950170-24-044015
    Summary Compensation Table
  7. 0000950170-23-012704
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Phathom Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PHAT (accessed 2026).
Short form: data: Velarion

The paid brief for Phathom Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Phathom Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Phathom Pharmaceuticals discloses

The companies named in PHAT's own disclosed peer group.

Aclaris Therapeutics, Inc.Arcus Biosciences, Inc.Arcutis Biotherapeutics, Inc.Ardelyx, Inc.Biohaven Ltd.Cogent Biosciences, Inc.Coherus Biosciences, Inc.Collegium Pharmaceuticals, Inc.Crinetics Pharmaceuticals, Inc.Deciphera Pharmaceuticals, Inc.Esperion Therapeutics, Inc.Evolus, Inc.Humacyte, Inc.Intercept Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.KalVista Pharmaceuticals, Inc.Kura Oncology, Inc.Mirum Pharmaceuticals, Inc.Nuvation Bio Inc.Protagonist Therapeutics, Inc.REGENXBIO Inc.Revance Therapeutics, Inc.Rhythm Pharmaceuticals, Inc.Rocket Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy